Ipsen and bioMerieux have decides to co identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.
bioMerieux board member Christian Brechot said their goal is to reinforce personalized medicine and contribute through this partnership to the novel paradigm in medicine, which is increasingly ‘patient-driven’ rather than ‘disease-driven.
Ipsen executive vice president, chief scientific officer Claude Bertrand said the shared vision and the cross-company synergies represent a unique opportunity to leverage early stage co-development of innovative products and biomarkers for patient care.